FDA Clears Gilead’s Trodelvy for First-Line Triple-Negative Breast Cancer

The regulatory green light follows Phase 3 trial results demonstrating that Trodelvy-based regimens significantly outperform standard chemotherapy in reducing the risk of disease progression or death. By moving into the first-line setting, the therapy expands its reach beyond its previously established role in second-line treatment.

Gilead Chief Medical Officer Dietmar Berger characterized the decision as the establishment of a new standard of care for a malignancy that has historically resisted conventional approaches. Triple-negative breast cancer represents approximately 15% of all breast cancer diagnoses, consistently presenting clinicians with fewer effective therapeutic options than other metastatic variants.